ADAM17 and neoplasm: For example, potent non-selective inhibitors of ADAM17 and ADAM10, such as INCB3619 and INCB7839 (aderbasib), have shown promise in reducing tumour growth alone or in combination with other chemotherapeutic agents when tested in preclinical models of breast cancer and NSCLC [182,183,184,189].